Literature DB >> 20304825

Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.

Jurjen Tel1, Annechien J A Lambeck, Luis J Cruz, Paul J Tacken, I Jolanda M de Vries, Carl G Figdor.   

Abstract

Plasmacytoid dendritic cells (pDCs) play a major role in shaping both innate and adaptive immune responses, mainly via their production of large amounts of type I IFNs. pDCs are considered to primarily present endogenous Ags and are thought not to participate in the uptake and presentation of Ags from the extracellular environment, in contrast to their myeloid counterparts, which efficiently endocytose extracellular particulates. In this study, we show that human pDCs are able to phagocytose and process particulate forms of Ag entrapped in poly(lactic-coglycolic acid) microparticles. Furthermore, pDCs were also able to sense TLR ligands (TLR-Ls) incorporated in these particles, resulting in rapid pDC activation and high IFN-alpha secretion. Combining a tetanus toxoid peptide and TLR-Ls (CpG C and R848) in these microparticles resulted in efficient pDC activation and concomitant Ag-specific T cell stimulation. Moreover, particulate Ag was phagocytosed and presented more efficiently than soluble Ag, indicating that microparticles can be exploited to facilitate efficient delivery of antigenic cargo and immunostimulatory molecules to pDCs. Together, our results show that in addition to their potency to stimulate innate immunity, pDCs can polarize adaptive immune responses against exogenous particulate Ag. These results may have important consequences for the development of new immunotherapeutic strategies exploiting Ag and TLR-Ls encapsulated in microparticles to target APC subsets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304825     DOI: 10.4049/jimmunol.0903286

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Pivotal advance: peritoneal cavity B-1 B cells have phagocytic and microbicidal capacities and present phagocytosed antigen to CD4+ T cells.

Authors:  David Parra; Aja M Rieger; Jun Li; Yong-An Zhang; Louise M Randall; Christopher A Hunter; Daniel R Barreda; J Oriol Sunyer
Journal:  J Leukoc Biol       Date:  2011-11-04       Impact factor: 4.962

2.  Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.

Authors:  Colin de Haar; Maud Plantinga; Nina Jg Blokland; Niek P van Til; Thijs Wh Flinsenberg; Viggo F Van Tendeloo; Evelien L Smits; Louis Boon; Lotte Spel; Marianne Boes; Jaap Jan Boelens; Stefan Nierkens
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

3.  A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors.

Authors:  Matthew J Goldstein; Bindu Varghese; Joshua D Brody; Ranjani Rajapaksa; Holbrook Kohrt; Debra K Czerwinski; Shoshana Levy; Ronald Levy
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

4.  A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes.

Authors:  Hong Zhang; Josh D Gregorio; Toru Iwahori; Xiangyue Zhang; Okmi Choi; Lorna L Tolentino; Tyler Prestwood; Yaron Carmi; Edgar G Engleman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-06       Impact factor: 11.205

5.  Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.

Authors:  Booyeon J Han; Joseph D Murphy; Shuyang Qin; Jian Ye; Taylor P Uccello; Jesse Garrett-Larsen; Brian A Belt; Peter A Prieto; Nejat K Egilmez; Edith M Lord; David C Linehan; Bradley N Mills; Scott A Gerber
Journal:  Immunol Invest       Date:  2020-06-04       Impact factor: 3.657

6.  CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.

Authors:  Phillip D Fromm; Michael S Papadimitrious; Jennifer L Hsu; Nicolas Van Kooten Losio; Nirupama D Verma; Tsun Ho Lo; Pablo A Silveira; Christian E Bryant; Cameron J Turtle; Rebecca L Prue; Peter Vukovic; David J Munster; Tomoko Nagasaki; Ross T Barnard; Stephen M Mahler; Sébastien A Anguille; Zwi Berneman; Lisa G Horvath; Kenneth F Bradstock; Douglas E Joshua; Georgina J Clark; Derek N J Hart
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

7.  Antigen cross-presentation by dendritic cell subsets: one general or all sergeants?

Authors:  Stefan Nierkens; Jurjen Tel; Edith Janssen; Gosse J Adema
Journal:  Trends Immunol       Date:  2013-03-27       Impact factor: 16.687

8.  Cross-linking of CD81 by HCV-E2 protein inhibits human intrahepatic plasmacytoid dendritic cells response to CpG-ODN.

Authors:  Zhengkun Tu; Ping Zhang; Haijun Li; Junqi Niu; Xia Jin; Lishan Su
Journal:  Cell Immunol       Date:  2013-08-02       Impact factor: 4.868

9.  Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages.

Authors:  M Joglekar; S Khandelwal; D B Cines; M Poncz; L Rauova; G M Arepally
Journal:  J Thromb Haemost       Date:  2015-07-14       Impact factor: 5.824

10.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.